Home › Research › Treatments
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation
Anat Fisher, Greg Carney, Ken Bassett, Neena L Chappell. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016-05-04
Topic: Drug trials: efficacy and safety
Plain-language summary
Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence. Median ChEI persistence until discontinuation or death was 9.37 months (95% confidence interval [CI] 9.0-39.7) and 17.6 months (95% CI 16.9-18.3) in patients who started therapy before and after the new policy, respectively. The propensity-adjusted hazard ratio for discontinuing therapy was 0.91 (95% CI 0.88-0.94). Similar patterns were observed for persistence with the first ChEI (propensity-adjusted hazard ratio of 0.94; 95% CI 0.91-0.98). In rivastigmine users, the hazard ratio was insignificant (0.98; 95% CI 0.92-1.02). The British Columbia ChEI coverage policy was associated with significantly prolonged persistence with donepezil and galantamine, but not rivastigmine.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fisher, A., Carney, G., Bassett, K., & Chappell, N. L. (2016). Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. https://doi.org/10.1016/j.jval.2016.03.1832
Vancouver
Fisher A, Carney G, Bassett K, Chappell NL. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016. doi:10.1016/j.jval.2016.03.1832. PMID: 27565287.
BibTeX
@article{fisher2016-27565287,
author = {Fisher, Anat and Carney, Greg and Bassett, Ken and Chappell, Neena L},
title = {{Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation}},
journal = {Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
year = {2016},
doi = {10.1016/j.jval.2016.03.1832},
pmid = {27565287},
url = {https://doi.org/10.1016/j.jval.2016.03.1832}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence.
- Median ChEI persistence until discontinuation or death was 9.37 months (95% confidence interval [CI] 9.0-39.7) and 17.6 months (95% CI 16.9-18.3) in patients who started therapy before and after the new policy, respectively.
- The propensity-adjusted hazard ratio for discontinuing therapy was 0.91 (95% CI 0.88-0.94).
- Similar patterns were observed for persistence with the first ChEI (propensity-adjusted hazard ratio of 0.94; 95% CI 0.91-0.98).
- In rivastigmine users, the hazard ratio was insignificant (0.98; 95% CI 0.92-1.02).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 54/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 30 of the 56 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27565287) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 30 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 30 of the 56 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.